|
BRPI0718247B1
(pt)
|
2006-11-08 |
2021-09-21 |
Neurocrine Biosciences, Inc. |
Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos
|
|
LT3061760T
(lt)
|
2008-09-18 |
2018-02-26 |
Auspex Pharmaceuticals, Inc. |
Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai
|
|
WO2011153157A2
(en)
*
|
2010-06-01 |
2011-12-08 |
Auspex Pharmaceutical, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
NZ705372A
(en)
|
2012-09-18 |
2018-07-27 |
Auspex Pharmaceuticals Inc |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
MX2015009719A
(es)
|
2013-01-31 |
2016-08-08 |
Auspex Pharmaceuticals Inc |
Inhibidores benzoquinolona de vmat2.
|
|
EP3049087A4
(en)
*
|
2013-09-27 |
2017-05-24 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
KR102391134B1
(ko)
*
|
2013-12-03 |
2022-04-28 |
오스펙스 파마슈티칼스, 인코포레이티드 |
벤조퀴놀린 화합물을 제조하는 방법
|
|
MX2016009817A
(es)
|
2014-01-27 |
2017-02-28 |
Auspex Pharmaceuticals Inc |
Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
|
|
EA201691582A1
(ru)
|
2014-02-07 |
2017-01-30 |
Оспекс Фармасьютикалз, Инк. |
Новые фармацевтические препараты
|
|
US9782398B2
(en)
*
|
2014-02-07 |
2017-10-10 |
Neurocrine Biosciences, Inc. |
Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
|
|
PE20161573A1
(es)
|
2014-02-13 |
2017-01-19 |
Incyte Corp |
Ciclopropilamina como inhibidor de la lsd1
|
|
CN112741835A
(zh)
*
|
2014-05-06 |
2021-05-04 |
纽罗克里生物科学有限公司 |
用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
|
|
WO2016127133A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
DK3265085T3
(da)
|
2015-03-06 |
2022-10-03 |
Auspex Pharmaceuticals Inc |
Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
|
|
MY191796A
(en)
|
2015-04-03 |
2022-07-15 |
Incyte Corp |
Heterocyclic compounds as lsd1 inhibitors
|
|
MY189806A
(en)
*
|
2015-06-23 |
2022-03-08 |
Neurocrine Biosciences Inc |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
KR102710120B1
(ko)
|
2015-08-12 |
2024-09-27 |
인사이트 홀딩스 코포레이션 |
Lsd1 저해제의 염
|
|
TW201720443A
(zh)
|
2015-10-09 |
2017-06-16 |
梯瓦製藥國際有限責任公司 |
用以治療帕金森氏症之經氘化左旋多巴、碳度巴、以及奧匹卡朋的組合
|
|
MA56137B1
(fr)
*
|
2015-10-30 |
2024-03-29 |
Neurocrine Biosciences Inc |
Sels de dihydrochlorure de valbénazine et leurs polymorphes
|
|
CA3009169A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Neurocrine Biosciences, Inc. |
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
|
US10479787B2
(en)
|
2016-04-22 |
2019-11-19 |
Lupin Limited |
Process for preparation of tetrabenazine and deutetrabenazine
|
|
EP3473623B1
(en)
*
|
2016-06-29 |
2020-07-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of nbi-98854, preparation method therefor and use thereof
|
|
EP3523300A1
(en)
*
|
2016-10-06 |
2019-08-14 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
TW201827051A
(zh)
|
2016-12-02 |
2018-08-01 |
美商神經性分泌生物科學公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
WO2018130345A1
(en)
|
2017-01-10 |
2018-07-19 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
MY203491A
(en)
*
|
2017-01-27 |
2024-06-30 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
US10954235B2
(en)
|
2017-02-27 |
2021-03-23 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
KR20200003791A
(ko)
|
2017-03-15 |
2020-01-10 |
오스펙스 파마슈티칼스, 인코포레이티드 |
듀테트라베나진의 유사체, 이의 제조 및 용도
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
RU2768738C2
(ru)
*
|
2017-04-01 |
2022-03-24 |
Адептио Фармасьютикалз Лимитед |
ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
*
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
PL3684333T3
(pl)
|
2017-09-21 |
2025-06-23 |
Neurocrine Biosciences, Inc. |
Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane
|
|
KR20250110361A
(ko)
*
|
2017-10-10 |
2025-07-18 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
US11306082B2
(en)
|
2017-11-08 |
2022-04-19 |
Foresee Pharmaceuticals Co., Ltd. |
Esters of dihydrotetrabenazine
|
|
US11384077B2
(en)
|
2017-11-22 |
2022-07-12 |
Assia Chemical Industries Ltd. |
Solid state form of Valbenazine
|
|
CA3086611C
(en)
|
2017-12-26 |
2023-07-25 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
MX2021001017A
(es)
|
2018-08-15 |
2021-04-19 |
Neurocrine Biosciences Inc |
Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2).
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
EP4015517A4
(en)
*
|
2019-08-12 |
2023-10-18 |
Geneora Pharma (Shijiazhuang) Co., Ltd. |
VMAT2 INHIBITOR AND PRODUCTION METHOD THEREOF AND USE THEREOF
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
WO2021050977A1
(en)
|
2019-09-13 |
2021-03-18 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
RS67052B1
(sr)
|
2021-03-22 |
2025-08-29 |
Neurocrine Biosciences Inc |
Vmat2 inhibitori i postupci primene
|
|
IL307826A
(en)
|
2021-04-26 |
2023-12-01 |
Neurocrine Biosciences Inc |
Processes for the synthesis of valbanazine
|
|
AU2022302155A1
(en)
|
2021-06-30 |
2024-02-08 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
|
|
WO2023278987A1
(en)
|
2021-06-30 |
2023-01-05 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the add-on treatment of schizophrenia
|
|
CA3245030A1
(en)
|
2022-03-07 |
2023-09-14 |
Neurocrine Biosciences Inc |
VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE OF A TOSYLATE OR DITOSYLATE SALT, INTENDED FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
|
|
EP4590676A1
(en)
|
2022-09-21 |
2025-07-30 |
Neurocrine Biosciences, Inc. |
Hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|